Skip to Main Content

Benjamin Cherry, MD, FACP

Assistant Professor of Medicine (General Medicine); Director, Internal Medicine Subinternship

Contact Information

Benjamin Cherry, MD, FACP

Research Summary

Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study

National Cancer Institute Clinical Trial #NCT01675141

  • Multiple myeloma is rarely curable, but it is treatable. Initial treatment is directed at controlling symptoms and reducing the number of myeloma cells. It continues until the cancer stops responding to treatment. At that time, treatment may switch to maintenance therapy, which is given to try to extend the response of the first therapy for as long as possible. Research suggests that lenalidomide maintenance therapy may delay the time for myeloma cells to start to grow and possibly improve survival.

  • Lenalidomide is a drug that may reduce or prevent the growth of cancer cells. This study examines the long-term effect of lenalidomide on immune cells. It will also look at the effects of extended treatment on the cancer and the immune system.


Research Interests

Curriculum; Health Policy; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Lung Diseases, Interstitial; Hematologic Neoplasms; Idiopathic Pulmonary Fibrosis; Quality Improvement

Selected Publications